89BIO INC's ticker is ETNB and the CUSIP is 282559103. A total of 70 filers reported holding 89BIO INC in Q1 2022. The put-call ratio across all filers is 0.12 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,559,162 | -33.5% | 100,982 | -18.4% | 0.00% | 0.0% |
| Q2 2023 | $2,346,351 | +9.2% | 123,818 | -12.3% | 0.00% | 0.0% |
| Q1 2023 | $2,149,319 | +1568.5% | 141,124 | +1294.6% | 0.00% | – |
| Q4 2022 | $128,815 | -72.4% | 10,119 | -87.4% | 0.00% | – |
| Q3 2022 | $467,000 | +60.5% | 80,581 | -10.8% | 0.00% | – |
| Q2 2022 | $291,000 | +193.9% | 90,361 | +244.0% | 0.00% | – |
| Q1 2022 | $99,000 | +4.2% | 26,265 | +261.0% | 0.00% | – |
| Q4 2021 | $95,000 | +10.5% | 7,276 | +67.1% | 0.00% | – |
| Q3 2021 | $86,000 | -38.6% | 4,355 | -42.0% | 0.00% | – |
| Q2 2021 | $140,000 | -14.6% | 7,512 | +8.3% | 0.00% | – |
| Q1 2021 | $164,000 | +1.2% | 6,939 | +4.8% | 0.00% | – |
| Q4 2020 | $162,000 | +113.2% | 6,623 | +122.5% | 0.00% | – |
| Q3 2020 | $76,000 | -13.6% | 2,977 | -32.3% | 0.00% | – |
| Q2 2020 | $88,000 | -25.4% | 4,400 | -6.1% | 0.00% | – |
| Q1 2020 | $118,000 | -27.6% | 4,687 | -24.3% | 0.00% | – |
| Q4 2019 | $163,000 | – | 6,193 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Orchard Capital Management, LLC | 551,879 | $7,025,420 | 2.36% |
| RA Capital Management | 8,955,410 | $114,002,369 | 2.31% |
| Cormorant Asset Management, LP | 2,550,000 | $32,462 | 2.17% |
| Deep Track Capital, LP | 3,850,000 | $49,010,500 | 2.06% |
| COMMODORE CAPITAL LP | 758,244 | $9,652 | 1.46% |
| Ikarian Capital, LLC | 454,000 | $5,779,419 | 1.39% |
| DAFNA Capital Management LLC | 324,173 | $4,126,722 | 1.16% |
| Parkman Healthcare Partners LLC | 332,880 | $4,237,562 | 1.13% |
| Boxer Capital, LLC | 1,400,000 | $17,822,000 | 0.94% |
| Orbimed Advisors | 3,658,869 | $46,577,402 | 0.89% |